Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is Dr. Duffy still working for NWBO or did he complete his mission and returned in Merck?
Dr. Duffy's presence could be a good indicator for NWBO's success!
The Market Journal ... Northwest Biotherapeutics etc. The market Study is segmented by key regions which is accelerating the marketization.
https://www.marketjournal.co.uk/emerging-cancer-vaccines-market-to-develop-new-growth-story-emerging-segments-is-the-key/51434/
Mr. Erik007tc - I think so too and I hope it will soon become reality!
Merck’s Keytruda Will Become Best-Selling Drug Worldwide, Research Group Says.
https://www.barrons.com/articles/mercks-keytruda-will-become-best-selling-drug-worldwide-research-group-says-51570204530
Oct. 4, 2019
Merck’s cancer drug Keytruda will be the best-selling drug in the world by 2023, according to a report on Friday from the research firm GlobalData.
GlobalData projected annual sales of Keytruda to hit $22.2 billion by 2025.
“Emerging as an effective treatment for a range of cancers, Keytruda has developed into Merck & Co’s biggest product,” GlobalData pharma analyst Keshalini Sabaratnam said in a statement.
Merck (MRK) reported $7.2 billion in Keytruda sales in 2018, and Wall Street analysts project $10.8 billion in 2019.
GlobalData’s estimate is more aggressive than the Wall Street consensus, which projects $19.9 billion in Keytruda sales by 2023.
The back story. Shares of Merck are up 9.7% this year, and 18% over the past 12 months. First approved in 2015, Keytruda boosts the immune system by inhibiting the so-called PD-1 pathway. Keytruda has been approved in many indications, and, according to Merck, is the subject of more than 1,000 ongoing trials.
What’s new. According to GlobalData, sales of Keytruda could outstrip sales of all other prescription drugs worldwide by 2023.
“Keytruda is expected to overtake AbbVie and Eisai Co’s anti-inflammatory drug Humira (adalimumab), which is currently the world’s top-selling drug,” Sabaratnam said in the statement. “It has received market approvals for over 20 oncology indications in the U.S., and is continuing to expand into new indications and markets globally.”
GlobalData projects that Eliquis, an anticoagulant sold by Bristol-Myers Squibb (BMY) and Pfizer (PFE), will be the second-best-selling drug by 2025, and that Celgene’s (CELG) Revlimid, a cancer drug, will be third. Opdivo, a Bristol-Myers Squibb drug that competes directly with Keytruda, will be fourth, according to the research group.
When the Bristol-Myers Squibb acquisition of Celgene is finalized, which is expected in the coming months, Bristol-Myers will own at least a piece of all three of those runners-up.
Looking forward. Keytruda continues to rack up indications. On Wednesday, Merck announced that Chinese regulators had approved the drug as a first-line treatment of patients with forms of non-small cell lung cancer. And at a cancer conference in Barcelona late last Month, Merck offered new data on Keytruda in patients with early-stage triple-negative breast cancer in combination with chemotherapy.
Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com
Congratulations, you are a medical encyclopedia, however it would be desirable to accelerate for approval DCvax L + D ...
Linda P. wake up! Tumors, there comes an effective drug against 29 types of neoplasms
September 29, 2019
https://www.en24.news/2019/09/tumors-there-comes-an-effective-drug-against-29-types-of-neoplasms.html
It is a "wild" drug that can hit 29 different types of cancer, in adults and children, thanks to its particular mechanism of action: it does not act, in fact, on the organ where the cancer originated but on the Ntrk gene alteration which can be common to cancer cells of many cancers; twenty-nine, precisely, those currently tested but could be many more.
The latest results on the effectiveness of the molecule (larotrectinib) were presented at the European Onmoology Congress of Esmo and are defined as "exceptional" by the scientific community: a 30% reduction in the tumor mass was recorded in 79% of the patients evaluated (on a sample of 153) and 75% of those with brain metastases, and the average survival is over 3 years.
The drug – technically defined as 'agnostic' because it does not target a particular organ, acting independently of the location of the tumor – is the first of its kind to have obtained, a few days ago, the green light by the EU Commission for marketing in Europe . The molecule acts on advanced or metastatic solid tumors in adult and pediatric patients for whom surgery would be too risky and which present a particular gene alteration called Ntrk gene fusion. It is a rare alteration but that in Italy affects about 4 thousand patients every year.
GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
December 10 -11 Boston, MA, USA
Time: 11:40 am
Day: day Two
DCVax Technology: Leveraging Activated Dentritic Cells in Clinical 40 for GBM
Details:
- Exploring the history, biology and development of the platform technology DCVax
- Outlining the key aspects of the DCVax technology that contribute to the positive clinical results
- Designed to mobilize the entire immune system
- Designed to target not just one but the full set of biomarkers on the patient’s tumor
- DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor
- Pinpointing highs and lows of clinical development to date
Speakers: Marnix Bosch
https://glioblastoma-drugdevelopment.com/seminar/dcvax-technology-leveraging-activated-dentritic-cells-in-clinical-40-for-gbm/
Texas Doctor Stephen M. Hahn Is a Top Contender to Head FDA
M.D. Anderson’s radiation-oncology chief is among three leading candidates for post open since April
https://www.wsj.com/articles/texas-doctor-stephen-m-hahn-is-a-top-contender-to-head-fda-11567635140
By Thomas M. Burton and Alex Leary https://www.wsj.com/news/author/8749
Updated Sept. 4, 2019 6:46 pm ET
Stephen M. Hahn, a senior executive and radiation oncologist at M.D. Anderson Cancer Center in Houston, has emerged as a leading candidate to be nominated by the Trump administration to become commissioner of the Food and Drug Administration, according to people familiar with the matter.
Dr. Hahn, 59 years old, is chief of radiation oncology and chief medical executive at M.D. Anderson, a research and clinical hospital affiliated with the University of Texas. He didn’t respond to phone calls or an email seeking comment. One person familiar with the events said Dr. Hahn now is the leading contender.
The Wall Street Journal previously reported that an unidentified M.D. Anderson physician was one of three leading contenders for the position. Also in the running are Norman E. “Ned” Sharpless, also an oncologist and currently the acting FDA commissioner; and Alexa Boer Kimball, a Harvard dermatology professor.
The White House declined to comment.
The senior post came open after former Commissioner Scott Gottlieb resigned in April.
Four other former FDA commissioners sent a letter to President Trump and Health and Human Services Secretary Alex Azar this week, praising Dr. Sharpless and recommending they name a permanent FDA commissioner.
“He has gained the respect of the agency staff and a broad spectrum of the public in support of the FDA’s mission,” said the letter signed by the former commissioners: Drs. Robert M. Califf, Margaret Hamburg, Andrew von Eschenbach and Mark McClellan.
Dr. Sharpless, 52, was director of the National Cancer Institute when Mr. Azar named him to become acting FDA commissioner. He might have the option of returning to the cancer institute should he not become permanent FDA commissioner.
Before joining M.D. Anderson in 2014, Dr. Hahn was at the University of Pennsylvania, where he served as a department chair and as a vice chair for research with the department of radiation oncology.
Earlier, he was a senior investigator at the National Cancer Institute from 1989 to 1995, and until 1995 was chief of the prostate-cancer clinic at the cancer institute’s clinical pharmacology branch.
Theodore S. Lawrence, chair of radiation oncology at the University of Michigan, said Dr. Hahn is “a great guy with a great personality, very outgoing and very perceptive on both the medical side and the financial side.”
Dr. Hahn is board-certified in medical oncology and radiation oncology, Dr. Lawrence said.
Dr. Kimball, 50, has degrees from Princeton University and Yale University Medical School, served a dermatology residency at Stanford University and had a clinical research fellowship at the National Institutes of Health. She has played a prominent role in several trials evaluating the safety of drugs for psoriasis.
—Alex Leary contributed to this article.
Write to Thomas M. Burton at tom.burton@wsj.com and Alex Leary at alex.leary@wsj.com
News from Yahoo Conversation:
Neil Woodford sold all his stock in NWBO.
Maybe it will hit the jackpot now. I doubt!
https://citywire.co.uk/money/woodford-buys-bat-bt-and-iag-in-ftse-100-spending-spree/a1263441
Startingboy is probably right in his posts below ...
Post 1567:
... the news say is a global licence so maybe AVXT still got some value or they use to r/m BIOVAXYS LLC into it in the future.
Post 1569:
... it looks like firebird fund take all the goodies from avxt to BioVaxys, so avxt is done or a shell.
A Second-Generation Dendritic Cell Cancer Vaccine Preparing to Shine
DCVax-L efficacy may correlate with tumor mutational burden, suggesting mechanism is operable Carlo Rago, PhD
July - November 12 th 2018
Updated February 18 th 2019
https://www.scribd.com/document/393282167/A-Second-Generation-Dendritic-Cell-Cancer-Vaccine-Preparing-to-Shine
You can contact Mr. Kovan with your words at the following email address, he will answer you within 24 hours:
kkovan@biovaxys.com
The shareholders will thank you if you want to share news on this board!
Chinese companies moving abroad to avoid trade war with the US
01/10/2019
Talks between US and Chinese delegations ended today. Beijing pledges to buy more from ...
http://www.asianews.it/news-en/Chinese-companies-moving-abroad-to-avoid-trade-war-with-the-US-45934.html
I don't know if you owner AVAX shares and if you are waiting-for a rebirth of AVAX, however I received Mr. Kovan's reply:
… BioVaxys is an entirely new entity and is separate from what was Avax. I do not know the specifics with Avax as I was never involved on their management team nor had any position with them. But from what I do know, Avax is no longer in business. BioVaxys just recently acquired some of the remaining unexpired Avax patents (which had been in default), and has also filed its own new IP on novel compositions/methods for achieving better efficacy across a broad range of tumor types. Avax was a very exciting company and made major progress with its melanoma and ovarian cancer programs, and it is unfortunate that they are no longer operating as I believe they could have saved lives with their vaccines. Although we intend to leverage some of that pedigree, we are doing it as a separate company with a somewhat different approach that we believe will be superior. …
* What do you think about, shareholders own only paper for the trash?
Thank you very much for links ... did you emailed Dr. Berd to find out if AVXT was abandoned along with the shareholders?
I think they took away the license with Vax technology and created a new biopharma called BioVaxys ...
Anyway, I can't understand how AVXT does to exist and survive on OTC market ...
I still own 100K AVXT shares that are worth a dinner at restaurant, I am undecided whether to sell now that AVXT is still listed on the OTC market ...
What do you advise me to do?
Happy New Year to You and Longer Shareholders!
Huawei Wang's research while affiliated with Nankai University and other places.
https://www.researchgate.net/scientific-contributions/2115183238_Huawei_Wang
You are right but love often comes immediately at first meeting ... again, it seems that undersigned business is all for benefit of NWBO ...
I wonder what deal Huawei has done ... NWBO's property was really necessary!
Could anyone explain what advantage Huawei had?
I hope that in addition of individual business there is a partnership between NWBO and Huawei to quickly reach each other's goals ...
1) DCVax-L approved immediately in China and India with help of Huawei ...
2) Huawei Healthcare Solutions initially supported by NWBO for development in U.K. and U.S. ... when NWBO will become a Big Pharma ...
Huawei Showcases its Healthcare Solutions at Next Generation Health Informatics India
http://www.hhmglobal.com/industry-updates/press-releases/huawei-showcases-its-healthcare-solutions-at-next-generation-health-informatics-india
With India’s healthcare market expected to grow by US $24 billion over the next two years there is an increased demand towards enabling next generation private medical services. Taking a cue from this scenario, Huawei Enterprise has showcased its Healthcare solutions at the Next Generation Health Informatics India conference in New Delhi.
Talking about Huawei’s unique offering for the healthcare segment under the topic of, “Adapting Next generation ICT Technologies for inclusive healthcare” Rajeev Khera, Head- Vertical Cluster , Huawei Telecommunications said that Huawei’s healthcare focused solutions are all about enabling next generation healthcare transformation for the healthcare industry. Huawei’s end to end ICT portfolio creates value for healthcare organizations to create right technology environment .
“According to WHO, Tele-Health or e-Health is the cost-effective and secure use of ICT technologies in support of health and health-related fields, including health-care services, health surveillance, health literature, and health education, knowledge and research. Keeping this in mind, it is our endeavor to provide our solutions expertise to help healthcare stakeholders in delivering faster, better and safer delivery of care for their patients,” he explained.
In today’s fast changing healthcare ecosystem, private healthcare providers are taking help of ICT solutions in order to standardize patient care across their enterprises, allowing them to stay ahead of the competitive and present an attractive proposition in front of their end customers.
With its proven ICT capabilities, Huawei has its portfolio of healthcare solutions which provide virtual health delivery, mobile care clinic, mobile collaboration, managed healthcare services, virtual clinic concept, remote surgery etc. All these solutions are directed towards hospitals, nursing homes, retailers, clinics, correctional institutions, educational facilities, government or corporate offices.
Huawei is a leading global information and communications technology (ICT) solutions provider. Through its dedication to customer-centric innovation and strong partnerships, the company has established end-to-end advantages in telecom networks, devices and cloud computing. Huawei is committed to creating maximum value for telecom operators, enterprises and consumers by providing competitive solutions and services. Huawei’s products and solutions have been deployed in over 140 countries, serving more than one third of the world’s population.
Huawei's vision is to enrich life through communication. By leveraging on the experience and expertise in the ICT sector, the company is helping towards bridging the digital divide by providing opportunities to enjoy broadband services, regardless of geographic location. Today, India is Huawei’s second largest market outside of China with an employee base of over 6,500 employees across the length and breadth of the country.
Zia Askari
Branding Manager – Enerprise Business
HUAWEI Telecommunications (India)
Unfortunately, speculation is bad jokes! Big Pharma, Naked Shorter, FDA ...
Perhaps it is likely that NWBO will soon get DCVax-L approval in China with 2 billion people, with the contribution of Huawei in probable partnership with NWBO ...
My fantasy or real business behind the scenes of NWBO to overcome all obstacles ...
I believe we will discover the agreements between Huawei and NWBO only after returning to Nasdaq over $ 10 per share ...
Probably a big center in Sawston / Cambridge to store data on Cloud !!!
Could Huawei wish to enter in U.S. stock market through NWBO?
https://www.investopedia.com/articles/investing/051215/how-invest-huawei.asp
Jul. 31, 2018
... Thirty-one years after its founding, Huawei Technologies Co. remains a private entity fully owned by company employees. That means the company is not traded on any public market and that people other than current employees cannot invest in it. ...
How Does Huawei Make Money?
Huawei operates in the carrier, enterprise, and consumer segments of the market. Because the company is not public and is not traded on any stock market, Huawei is not required to submit filings to the Securities Exchange Commission (SEC). ...
... In 2014, upper management at Huawei was asked if it would consider a stock market listing, but the idea was immediately rejected. ...
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction.
https://finance.yahoo.com/news/nw-bio-announces-non-dilutive-133200994.html
""BETHESDA, Md., Dec. 11, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements with a large multi-national corporation for a package transaction involving the Company's property located near Cambridge, UK. Pursuant to these agreements," data-reactid="11"BETHESDA, Md., Dec. 11, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements with a large multi-national corporation for a package transaction involving the Company's property located near Cambridge, UK. Pursuant to these agreements,
The Company will sell most of its UK property to the multi-national corporation.
The Company will receive £37.5 million (approximately $47.3 million) cash payment at closing.
The Company will retain ownership of 17 acres of the property, which are excluded from the sale and which the Company believes will have substantial additional value in the future.
The Company will retain a lease-back of the approximately 87,000 square foot manufacturing facility which the Company has been developing on the site, along with substantial adjacent areas, for up to 40 years on favorable terms.
The cash purchase price to be paid for the sale of most of the UK property will provide approximately $47.3 million of non-dilutive gross proceeds. Transaction expenses for broker and legal fees are expected to total about £1.3 million. The Company plans to use the transaction proceeds for Company obligations and operations.
£&The Company acquired the property for approximately £18 million. The Company's subsequent investments into the property have been focused on the 87,000 square foot manufacturing facility, including refurbishments, structural improvements, extension of an additional level of interior space, and buildout of initial clean-room manufacturing suites. The Company will retain the value and use of these investments through the favorable lease-back of this manufacturing facility. The Company also retains the freedom to make further alterations, additions and improvements.
&£&The lease-back of the manufacturing facility will initially be for 20 years, with a renewal for a second 20 years on the same terms at the Company's option. The rent is determined by valuing the entire manufacturing facility as a warehouse. No rent is payable for the first year. Starting in year two, the rent is approximately £5.76 per square foot per year, with limited adjustments once every five years.
&®&The lease includes substantial adjacent areas, including for surface parking of 600 vehicles and for equipment, plant and facilities that support or are related to operations in the manufacturing facility. The Company believes that, with internal buildout of further manufacturing suites inside this facility, it will potentially be capable of supporting production of DCVax® products for up to 10,000 patients per year.
&The property and the manufacturing facility are situated in the heart of the "Golden Triangle" of leading academic centers and rapidly developing R&D centers, from which the Company can draw the technical personnel needed for its operations. The property and manufacturing facility are also situated on or near major transportation arteries, including nearby Stanstead Airport, the major air shipping hub.
®®"Now that the data from our Phase 3 clinical trial of DCVax®-L have further matured and provided a further encouraging picture of patient survival, and we are ready to move forward with the months of work related to completion of the trial, we are very pleased to have a new war chest of funding for this work," commented Linda Powers, CEO of NW Bio. "We are also looking forward to proceeding with further DCVax®-Direct trials."
&"We are especially pleased to obtain this funding on a non-dilutive basis, and to seamlessly continue our activities with the UK manufacturing facility under the favorable lease-back."
Flipp, please just a clarification about property:
- Who is own, Cognate or NWBO ???
I have not been on the board for a long time ... too much stress waiting for approval ...
Thanks!
-------------------------------------------------------
Quote:
The Company’s property is located at the crossroads of major rail, truck and air access about 50 miles North of London, on the southern edge of Cambridge, and close to Stanstead airport (which serves as a major air shipping hub).
Mrs. Linda Power, I suggest you move with FDA, otherwise in few years DCVax L and D will never be used ... Best regards from a NWBO's shareholder
---------------------------------------------------------------
Scientists discover kill code in all cells that can be triggered to destroy cancer.
Oct 29 2018
A “kill code” present within every cell of the body can cause cancerous cells to self-destruct, according to a study recently published in the journal Nature Communications.
https://www.news-medical.net/news/20181029/Scientists-discover-kill-code-in-all-cells-that-can-be-triggered-to-destroy-cancer.aspx
-------------------------------------------------------------
DETAILS in the journal NATURE COMMUNICATIONS:
6mer seed toxicity in tumor suppressive microRNAs
https://www.nature.com/articles/s41467-018-06526-1
The Brain Tumour Charity submits DCVax®-L consultation response.
...If DCVax®-L is approved by NICE, then the NHS is legally obligated to make the treatment available within three months...
...The Charity will now form part of a NICE appraisal committee in early November where researchers, clinicians, patient representatives and relevant bodies will be brought together to discuss the treatment's suitability for uptake...
...We look forward to being part of the committee in November and will continue to feed into the overall process to ensure promising treatments are made available for those who need it most.
https://www.thebraintumourcharity.org/media-centre/news/policy-news/brain-tumour-charity-submits-dcvax-l-consultation/
NICE
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]
As you will be aware, the Department of Health has asked NICE to conduct an appraisal of DCVax-L for treating newly diagnosed glioblastoma Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-August 2018
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
Technology appraisal guidance
https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer:
Is it AVAX ???
Science Translational Medicine 11 Apr 2018:
1) Janos L. Tanyi
Ovarian cancer research center
Abramson Cancer Center, Perelman School of Medicine,
University of Pennsylvania, Philadephia, PA 19104, USA
6) Drew A. Torigian - Harvey L. Nisenbau ... Philadephia, PA 19104, USA
7) Carl H. June - Bruce L. Levine ... Philadephia, PA 19104, USA
8) Rosemarie Mick ... Philadephia, PA 19104, USA
SOURCE: http://stm.sciencemag.org/content/10/436/eaao5931
Full text without login:
https://drive.google.com/open?id=1cQeb_Ev-nEnfdPoRqGPpkPpPQt75bpYI
Last-minute job offers in Cognate Bioservices.
Someone rightly noticed that job offers are often repeated after 2 weeks ...
Probably Cognate cannot find the right people ... they have urgency and repeat job offers:
Manager, Manufacturing Support
https://www.linkedin.com/jobs/view/manager%2C-manufacturing-support-at-cognate-bioservices-507231133?trkInfo=searchKeywordString%3ACognate%2BBioservices%2CsearchLocationString%3A%252C%2B%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A5%2CMSRPsearchId%3Add9ebe97-83c7-4afb-8ced-09890ae646ff&refId=dd9ebe97-83c7-4afb-8ced-09890ae646ff&trk=jobs_jserp_job_listing_text
Quality Control Scientist
https://www.linkedin.com/jobs/view/quality-control-scientist-at-cognate-bioservices-507228548?trkInfo=searchKeywordString%3ACognate%2BBioservices%2CsearchLocationString%3A%252C%2B%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A6%2CMSRPsearchId%3Ac7e961b8-a046-4fa4-949f-65d352c6af3a&refId=c7e961b8-a046-4fa4-949f-65d352c6af3a&trk=jobs_jserp_job_listing_text
Training and Development Manager
https://www.linkedin.com/jobs/view/training-and-development-manager-at-cognate-bioservices-507229956?trkInfo=searchKeywordString%3ACognate%2BBioservices%2CsearchLocationString%3A%252C%2B%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A12%2CMSRPsearchId%3Adb3ccc8b-bb2d-44bc-9bda-bd32e82577df&refId=db3ccc8b-bb2d-44bc-9bda-bd32e82577df&trk=jobs_jserp_job_listing_text
.
News job offer in Cognate Bioservices today:
1) Associate Director, Quality Operations
2) Associate Director, Quality Systems
3) QC Raw Materials Analyst I
4) Quality Control Scientist
https://www.linkedin.com/jobs/search?keywords=cognate+bioservices&location=stati+uniti&locationId=&trk=jobs_jserp_search_button_execute&orig=JSERP&applyLogin=
.
Important Dates:
Updated Date: 2017-10-23
Created Date: 2006-09-28
Registrar Expiration Date: 2019-09-28
------------------------------------------------------------------
Raw WHOIS Record
Domain Name: intellectns.com
Registry Domain ID: 611998298_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.srsplus.com
Registrar URL: http://srsplus.com
Updated Date: 2017-10-23T20:34:35Z
Creation Date: 2006-09-28T14:31:08Z
Registrar Registration Expiration Date: 2019-09-28T14:31:08Z
Registrar: TLDS LLC. d/b/a SRSPlus
Registrar IANA ID: 320
Reseller:
Domain Status: clientTransferProhibited http://icann.org/epp#clientTransferProhibited
Registry Registrant ID:
Registrant Name: Elliot Maza
Registrant Organization:
Registrant Street: 550 Sylvan Ave Suite 101
Registrant City: Englewood Cliffs
Registrant State/Province: NJ
Registrant Postal Code: 07632
Registrant Country: US
Registrant Phone: +1.2016085101
Registrant Phone Ext.:
Registrant Fax:
Registrant Fax Ext.:
Registrant Email: emaza@elliotmaza.com
Registry Admin ID:
Admin Name: Elliot Maza
Admin Organization:
Admin Street: 550 Sylvan Ave Suite 101
Admin City: Englewood Cliffs
Admin State/Province: NJ
Admin Postal Code: 07632
Admin Country: US
Admin Phone: +1.2016085101
Admin Phone Ext.:
Admin Fax:
Admin Fax Ext.:
Admin Email: emaza@elliotmaza.com
Registry Tech ID:
Tech Name: Tim Hyatt
Tech Organization:
Tech Street: 550 Sylvan Ave
Tech City: Englewood Cliffs
Tech State/Province: NJ
Tech Postal Code: 07632
Tech Country: US
Tech Phone: +1.8884928841
Tech Phone Ext.:
Tech Fax:
Tech Fax Ext.:
Tech Email: domains@hyattcomputer.com
Name Server: dns2.srsplus.com
Name Server: dns1.srsplus.com
DNSSEC: Unsigned
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8773812449
---------------------------------------------------------------
CHECK below:
https://whois.icann.org/en/lookup?name=intellectns.com
.
Statement from FDA Commissioner Scott Gottlieb, M.D., on new FDA efforts to support more efficient development of targeted therapies.
December 15, 2017
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589248.htm
FDA guides on molecular targeted therapies beyond cancer.
Dec 15, 2017
https://www.biocentury.com/bc-extra/politics-policy/2017-12-15/fda-guides-molecular-targeted-therapies-beyond-cancer
.
New job on Cognate Bio:
1) Training and Development Manager
2) Director, Facilities
3) Inventory Supervisor - Biotech
4) QC Analyst II - Bioassays (... Understanding/familiarity with relevant FDA, EMA, ICH, USP and EP guidelines and regulations associated with the quality control of biologic/cell therapies...)
https://www.linkedin.com/jobs/search?keywords=cognate+bioservices&location=Stati+Uniti&trk=jobs_jserp_search_button_execute&orig=JSERP&applyLogin=&locationId=us%3A0
.
I hope to see within 3 months:
1) Merger NWBO + Cognate + Advent
2) Buyout
3) Approval DCvaxL + Direct (on the same day)
EMA (European Medicines Agency) will move to Amsterdam after March 2019.
Amsterdam wins fight for EU medical agency
http://www.cetusnews.com/business/Amsterdam-wins-fight-for-EU-medical-agency.rkrY6MqegG.html
.
Happy-L, I expect a DCvax-L + D contemporary approval ...
I thank you so much for your detailed information.
Unfortunately, I did not read your post in July!
.
Please, have you a link?
Or, is it just your feeling?
Confirmation of NWBO's positive data...
Evaluate, thanks very much for link and for your great discovery that Advent already since August was looking for employees for the site in Sawston.
I believe that we are all excited about this news (the shareholders, the diseased and their family members).
Unfortunately, I have not seen any comments on this board...
Probably, they were distracted or they were attracted to the important news disclosed by the FDA!
I would like to invite anyone to read the following on the link below:
http://uk-jobs.pro/offers/2946d256fccfcebc/quality-assurance-manager-jobs-advent-bioservices-sawston-august-2017
.